#ASCO25: PCCTC investigator Dr Rana McKay discusses the COMRADE study, "The combination of olaparib with radium-223 demonstrated feasibility, safety, and antitumor activity in patients with metastatic castration-resistant #prostatecancer with bone metastases”
Olaparib Plus Radium-223 Generates Superior rPFS in CRPC
#CRPC #ProstateCancer #ASCO25 @ascocancer.bsky.social
www.onclive.com/view/olapari...
#CRPC #ProstateCancer #ASCO25 @ascocancer.bsky.social
www.onclive.com/view/olapari...
Olaparib Plus Radium-223 Generates Superior rPFS in CRPC
Olaparib/radium-223 demonstrated superior rPFS outcomes compared with radium-223 alone in patients with castration-resistant prostate cancer.
www.onclive.com
June 3, 2025 at 9:20 PM
#ASCO25: PCCTC investigator Dr Rana McKay discusses the COMRADE study, "The combination of olaparib with radium-223 demonstrated feasibility, safety, and antitumor activity in patients with metastatic castration-resistant #prostatecancer with bone metastases”
PCCTC study of a novel CTLA-engaging IO plus Lu177-PSA-617 therapy in patients with metastatic castration-resistant #prostatecancer (mCRPC) at #ASCO25 #MedIQASCO25 with @tiansterzhangmd.bsky.social. Clear activity and safe!
June 3, 2025 at 1:30 PM
PCCTC study of a novel CTLA-engaging IO plus Lu177-PSA-617 therapy in patients with metastatic castration-resistant #prostatecancer (mCRPC) at #ASCO25 #MedIQASCO25 with @tiansterzhangmd.bsky.social. Clear activity and safe!
Join us tomorrow (Tuesday) at #ASCO25 as PCCTC investigators present at the prostate cancer oral abstract session (Hall D1 and Live Stream)!
June 2, 2025 at 4:11 PM
Join us tomorrow (Tuesday) at #ASCO25 as PCCTC investigators present at the prostate cancer oral abstract session (Hall D1 and Live Stream)!
#ASCO25: PCCTC investigators Drs Karen Autio, Michael Schweizer, and Mark Stein contribute to first-in-human results for novel T-cell engager pasritamig (JNJ-78278343), showing early anti-tumor activity in #prostatecancer www.jnj.com/media-center...
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse ev...
www.jnj.com
June 1, 2025 at 2:19 PM
#ASCO25: PCCTC investigators Drs Karen Autio, Michael Schweizer, and Mark Stein contribute to first-in-human results for novel T-cell engager pasritamig (JNJ-78278343), showing early anti-tumor activity in #prostatecancer www.jnj.com/media-center...
The PCCTC at #ASCO25 via UroToday: A Randomized, Open-Label, Phase 2b Study of the Bromodomain Inhibitor ZEN-3694 + Enzalutamide vs Enzalutamide in Patients with mCRPC www.urotoday.com/conference-h...
ASCO 2025: A Randomized, Open-Label, Phase 2b Study of the Bromodomain Inhibitor ZEN-3694 + Enzalutamide versus Enzalutamide in Patients with mCRPC
ASCO 2025 bromodomain inhibitor ZEN-3694 + enzalutamide, enzalutamide, metastatic castration resistant prostate cancer (mCRPC), PSA50 response.
www.urotoday.com
June 1, 2025 at 2:04 PM
The PCCTC at #ASCO25 via UroToday: A Randomized, Open-Label, Phase 2b Study of the Bromodomain Inhibitor ZEN-3694 + Enzalutamide vs Enzalutamide in Patients with mCRPC www.urotoday.com/conference-h...
Today at #ASCO25, Rapid Oral Sessions featuring PCCTC #prostatecancer science: the phase 2 Metacure trial, the novel B7H3 ADC DB‑1311/BNT324, and the phase 1 study results of JNJ-78278343
June 1, 2025 at 1:04 PM
Today at #ASCO25, Rapid Oral Sessions featuring PCCTC #prostatecancer science: the phase 2 Metacure trial, the novel B7H3 ADC DB‑1311/BNT324, and the phase 1 study results of JNJ-78278343
#ASCO25 is just days away. Be sure to check out the innovative PCCTC prostate cancer clinical research presented at this year's annual meeting in Chicago!
May 28, 2025 at 6:38 PM
#ASCO25 is just days away. Be sure to check out the innovative PCCTC prostate cancer clinical research presented at this year's annual meeting in Chicago!
We are excited to announce science from innovative PCCTC multi-center prostate cancer studies will be represented by 16 abstracts at #ASCO25!
May 22, 2025 at 9:05 PM
We are excited to announce science from innovative PCCTC multi-center prostate cancer studies will be represented by 16 abstracts at #ASCO25!
Dr. Shannon Westin presented results at #ASCO25 on how circulating tumor DNA could help personalize care for patients with endometrial cancer. The findings offer insights that may guide first-line treatment. Watch the video to learn more.
#EndCancer @ascocancer.bsky.social
#EndCancer @ascocancer.bsky.social
June 3, 2025 at 2:33 PM
Dr. Shannon Westin presented results at #ASCO25 on how circulating tumor DNA could help personalize care for patients with endometrial cancer. The findings offer insights that may guide first-line treatment. Watch the video to learn more.
#EndCancer @ascocancer.bsky.social
#EndCancer @ascocancer.bsky.social
Dr. Eric Singhi shares his excitement about the lung cancer research being presented at #ASCO25. Hear how this year’s meeting highlights the continued momentum in advancing the field and improving patient outcomes. #EndCancer @lungoncdoc.bsky.social
June 2, 2025 at 7:39 PM
Dr. Eric Singhi shares his excitement about the lung cancer research being presented at #ASCO25. Hear how this year’s meeting highlights the continued momentum in advancing the field and improving patient outcomes. #EndCancer @lungoncdoc.bsky.social
At #ASCO25, Dr. Jason Mouabbi presented new research on invasive lobular carcinoma, revealing distinct genomic alterations compared to other breast cancer subtypes. This highlights the potential for tailored treatment strategies based on unique mutational patterns. #EndCancer @jamouabbi.bsky.social
June 2, 2025 at 4:59 PM
At #ASCO25, Dr. Jason Mouabbi presented new research on invasive lobular carcinoma, revealing distinct genomic alterations compared to other breast cancer subtypes. This highlights the potential for tailored treatment strategies based on unique mutational patterns. #EndCancer @jamouabbi.bsky.social
At #ASCO25, Dr. Fumiko Chino shares findings from her research on cancer misinformation online. Hear how better understanding online information can help support patients and guide meaningful conversations in the clinic. #EndCancer @fumikochino.bsky.social
June 2, 2025 at 1:36 AM
At #ASCO25, Dr. Fumiko Chino shares findings from her research on cancer misinformation online. Hear how better understanding online information can help support patients and guide meaningful conversations in the clinic. #EndCancer @fumikochino.bsky.social
“There is almost no downside to exercise. It should be a part of the standard treatment for colon cancer,” says Dr. Nancy You, medical director of our Young-Onset Colorectal Cancer Program, in this @nbcnews.com piece on a new #ASCO25 study. @ascocancer.bsky.social
Read more: bit.ly/4kLt8Ib
Read more: bit.ly/4kLt8Ib
Exercise may benefit colon cancer patients as much as some drugs
Sticking to an exercise program after colon cancer treatment was linked to a 28% lower risk of the cancer returning, a new cancer diagnosis or death.
bit.ly
June 1, 2025 at 5:46 PM
“There is almost no downside to exercise. It should be a part of the standard treatment for colon cancer,” says Dr. Nancy You, medical director of our Young-Onset Colorectal Cancer Program, in this @nbcnews.com piece on a new #ASCO25 study. @ascocancer.bsky.social
Read more: bit.ly/4kLt8Ib
Read more: bit.ly/4kLt8Ib
At #ASCO25, MD Anderson experts share how supportive care can help head and neck cancer patients manage speech, swallowing, and nutrition challenges.
Hear how personalized care improves life beyond treatment: http://spr.ly/63328N7wWs #EndCancer
Hear how personalized care improves life beyond treatment: http://spr.ly/63328N7wWs #EndCancer
June 1, 2025 at 3:00 PM
At #ASCO25, MD Anderson experts share how supportive care can help head and neck cancer patients manage speech, swallowing, and nutrition challenges.
Hear how personalized care improves life beyond treatment: http://spr.ly/63328N7wWs #EndCancer
Hear how personalized care improves life beyond treatment: http://spr.ly/63328N7wWs #EndCancer
At #ASCO25, Dr. Tina Cascone presented promising results from the Phase II NeoCOAST-2 trial, also published in Nature Medicine. Adding novel agents like Dato-DXd to pre-surgical chemo-immunotherapy improved response rates in early-stage NSCLC. #EndCancer
bit.ly/4kIwuLT
bit.ly/4kIwuLT
June 1, 2025 at 11:30 AM
At #ASCO25, Dr. Tina Cascone presented promising results from the Phase II NeoCOAST-2 trial, also published in Nature Medicine. Adding novel agents like Dato-DXd to pre-surgical chemo-immunotherapy improved response rates in early-stage NSCLC. #EndCancer
bit.ly/4kIwuLT
bit.ly/4kIwuLT
Our Dr. Mir Lim, a fellow in Cancer Medicine, shared a new analysis of complement activation signatures in colorectal cancer, which will help guide future therapeutic strategies. @ascocancer.bsky.social @vanmorrismd.bsky.social @skopetz.bsky.social
#ASCO25 #EndCancer
#ASCO25 #EndCancer
May 31, 2025 at 5:47 PM
Our Dr. Mir Lim, a fellow in Cancer Medicine, shared a new analysis of complement activation signatures in colorectal cancer, which will help guide future therapeutic strategies. @ascocancer.bsky.social @vanmorrismd.bsky.social @skopetz.bsky.social
#ASCO25 #EndCancer
#ASCO25 #EndCancer
Our Pediatrics fellow, Dr. Jiasen He presented data on Delta-24-RGDOX-IL15, a novel oncolytic adenovirus with promising anti-tumor effects for primary and metastatic brain tumors, in combination with cellular therapies. @ascocancer.bsky.social @juanfueyo.bsky.social
#ASCO25 #EndCancer
#ASCO25 #EndCancer
May 31, 2025 at 5:47 PM
Our Pediatrics fellow, Dr. Jiasen He presented data on Delta-24-RGDOX-IL15, a novel oncolytic adenovirus with promising anti-tumor effects for primary and metastatic brain tumors, in combination with cellular therapies. @ascocancer.bsky.social @juanfueyo.bsky.social
#ASCO25 #EndCancer
#ASCO25 #EndCancer
Working with our Dr. Ryan Huey, postdoctoral fellow Dr. Joelle Allam shared results from the first characterization of the tumor microenvironment in patients with cancer of unknown primary. @ascocancer.bsky.social #ASCO25 #EndCancer @rwhuey.bsky.social
May 31, 2025 at 5:47 PM
Working with our Dr. Ryan Huey, postdoctoral fellow Dr. Joelle Allam shared results from the first characterization of the tumor microenvironment in patients with cancer of unknown primary. @ascocancer.bsky.social #ASCO25 #EndCancer @rwhuey.bsky.social
Our Dr. Prapassorn Thirasastr, a research scientist in Sarcoma Medical Oncology, showcased work done with our Dr. Neeta Somaiah and @elise-nassifhaddad.bsky.social on the characterization of patients with NF1 and non-NF1 malignant peripheral nerve sheath tumors. @ASCO
#ASCO25 #EndCancer
#ASCO25 #EndCancer
May 31, 2025 at 5:47 PM
Our Dr. Prapassorn Thirasastr, a research scientist in Sarcoma Medical Oncology, showcased work done with our Dr. Neeta Somaiah and @elise-nassifhaddad.bsky.social on the characterization of patients with NF1 and non-NF1 malignant peripheral nerve sheath tumors. @ASCO
#ASCO25 #EndCancer
#ASCO25 #EndCancer
Dr. Christopher Flowers spoke to a full room at STAT@ASCO about improving lives through research-driven patient care.
His message was clear. Research and care go hand in hand. #ASCO25 #EndCancer @statnews.com
His message was clear. Research and care go hand in hand. #ASCO25 #EndCancer @statnews.com
May 31, 2025 at 12:24 AM
Dr. Christopher Flowers spoke to a full room at STAT@ASCO about improving lives through research-driven patient care.
His message was clear. Research and care go hand in hand. #ASCO25 #EndCancer @statnews.com
His message was clear. Research and care go hand in hand. #ASCO25 #EndCancer @statnews.com
Genetic testing can be life-changing, but only if patients can access it. At #ASCO25, we spoke with MD Anderson’s Julie Moskowitz about her work to simplify and expand germline testing for young-onset colorectal cancer. #EndCancer @gcjuliemosk.bsky.social
May 30, 2025 at 10:05 PM
Genetic testing can be life-changing, but only if patients can access it. At #ASCO25, we spoke with MD Anderson’s Julie Moskowitz about her work to simplify and expand germline testing for young-onset colorectal cancer. #EndCancer @gcjuliemosk.bsky.social
Dr. Fumiko Chino presented at #ASCO25 that most patients want to talk about the cost of cancer care, but very few do.
Understanding and addressing cost concerns is an important part of supporting patients through treatment. #EndCancer @fumikochino.bsky.social
Understanding and addressing cost concerns is an important part of supporting patients through treatment. #EndCancer @fumikochino.bsky.social
May 30, 2025 at 7:36 PM
Dr. Fumiko Chino presented at #ASCO25 that most patients want to talk about the cost of cancer care, but very few do.
Understanding and addressing cost concerns is an important part of supporting patients through treatment. #EndCancer @fumikochino.bsky.social
Understanding and addressing cost concerns is an important part of supporting patients through treatment. #EndCancer @fumikochino.bsky.social
MD Anderson is leading the way in cancer research, from lab to clinic and from data to discovery. At #ASCO25, we’re showcasing the incredible progress we’re making, one step at a time. Follow along to see how we’re driving change! #EndCancer
May 30, 2025 at 5:43 PM
MD Anderson is leading the way in cancer research, from lab to clinic and from data to discovery. At #ASCO25, we’re showcasing the incredible progress we’re making, one step at a time. Follow along to see how we’re driving change! #EndCancer
A new triple-drug combo led by MD Anderson researchers has doubled overall survival in patients with BRAF V600E–mutated metastatic colorectal cancer. The BREAKWATER trial results, presented at #ASCO25, are a major step forward for precision oncology.
http://spr.ly/63321NfDEN
http://spr.ly/63321NfDEN
ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer
First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the Phase III BREAKWATER trial led by researchers from The University of Texas MD Anderson Cancer Center.
spr.ly
May 30, 2025 at 12:06 PM
A new triple-drug combo led by MD Anderson researchers has doubled overall survival in patients with BRAF V600E–mutated metastatic colorectal cancer. The BREAKWATER trial results, presented at #ASCO25, are a major step forward for precision oncology.
http://spr.ly/63321NfDEN
http://spr.ly/63321NfDEN
MD Anderson researchers are sharing over 120 studies at #ASCO25, including five with the potential to transform treatment for thyroid, colorectal and a rare blood cancer.
Explore how these new therapies could impact the future of care: http://spr.ly/63328N2lA0 #EndCancer
Explore how these new therapies could impact the future of care: http://spr.ly/63328N2lA0 #EndCancer
5 emerging therapies presented at ASCO 2025
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson's appointment process, our information page may be the best place to start.
spr.ly
May 28, 2025 at 9:00 PM
MD Anderson researchers are sharing over 120 studies at #ASCO25, including five with the potential to transform treatment for thyroid, colorectal and a rare blood cancer.
Explore how these new therapies could impact the future of care: http://spr.ly/63328N2lA0 #EndCancer
Explore how these new therapies could impact the future of care: http://spr.ly/63328N2lA0 #EndCancer